Publications by authors named "A Wenger"

A major challenge in epigenetics is uncovering the dynamic distribution of nucleosomes and other DNA-binding proteins, which plays a crucial role in regulating cellular functions. Established approaches such as ATAC-seq, ChIP-seq, and CUT&RUN provide valuable insights but are limited by the ensemble nature of their data, masking the cellular and molecular heterogeneity that is often functionally significant. Recently, long-read sequencing technologies, particularly Single Molecule, Real-Time (SMRT/PacBio) sequencing, have introduced transformative capabilities, such as N-methyladenine (6mA) footprinting.

View Article and Find Full Text PDF

Ten percent of children with cancer harbour a mutation in a predisposition gene. In children with the kidney cancer, Wilms tumour, the prevalence is as high as 30%. Certain predispositions are associated with defined histological and clinical features, suggesting differences in tumourigenesis.

View Article and Find Full Text PDF

Background: Recent trends in Switzerland indicate a concerning rise in simultaneous polysubstance use among adolescents, a practice marked by the concurrent or sequential consumption of multiple psychoactive substances, notably alcohol and cannabis, alongside prescription medications (e.g. benzodiazepines) and illicit drugs, resulting in dozens of fatal outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • The Genome in a Bottle Consortium (GIAB) is creating matched tumor-normal samples that are publicly consented for sharing genomic data and cell lines, focusing on pancreatic ductal adenocarcinoma (PDAC).
  • They provide a comprehensive genomic dataset from the first individual, combining high-depth DNA from tumor and normal cells using advanced whole genome sequencing technologies.
  • This open-access resource aims to help develop benchmarks for detecting genetic variants in cancer, fostering innovation in genome measurement and analysis tools.
View Article and Find Full Text PDF

KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) are suggested to vary in oncogenicity but the implications for human patients have not been explored in depth. We examined 1,360 consecutive PDAC patients undergoing surgical resection and find that KRAS mutations are enriched in early-stage (stage I) disease, owing not to smaller tumor size but increased node-negativity. KRAS tumors are associated with decreased distant recurrence and improved survival as compared to KRAS.

View Article and Find Full Text PDF